Litcius/Paper detail

All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: No

Dalia Rotstein

2022Multiple Sclerosis Journal12 citationsDOIOpen Access PDF

Topics & Concepts

Bruton's tyrosine kinaseTyrosine kinaseMedicineMultiple sclerosisInternal medicineImmunologyReceptorChronic Lymphocytic Leukemia ResearchChronic Myeloid Leukemia TreatmentsPI3K/AKT/mTOR signaling in cancer
All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: No | Litcius